Sarbajit Mukherjee MD MS

PubMed

• The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis.
  Kota Tokunaga, Yu Fujiwara, Reo Omori, Takumi Sato, Manmeet Singh Ahluwalia
  Targeted Oncology. 2025-11-01
• 1 citations
  Effects of Neighborhood Deprivation Index on Survival in Gastroesophageal Adenocarcinoma.
  Sawyer Bawek, Mrinalini Ramesh, Malak Alharbi, Nour Nassour, Kayla Catalfamo
  Healthcare. 2025-09-13
• Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer.
  Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S Bhakta, Patrick M Boland
  Cancer Medicine. 2025-08-01

Journal Articles

• Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.  
  Huang H, Salavaggione O, Rivera L, Mukherjee S, Brekken R, Tennant B, Iyer R, Adjei A., Arch Biochem Biophys, 11/12/2018

Abstracts/Posters

• Can DNA Methylation Patterns be used as Predictive Biomarkers for Chemotherapy Response in Osteosarcoma?
  Mukherjee S, Jeffries M, Rivas A, Malik R, Ibrahimi S, Fung K, White J, Meyer W, Vesely S, Barkauskas D, Hall D, Cherry M., J Clin Oncol 36, 2018 (suppl; abstr 11525), 6/1/2018
• Efficacy of PD-1/PD-L1 Therapy: do proton pump inhibitors affect the outcome?
  Mukherjee S, Khalid B, Ibrahimi S, Morton J, Roman D, Zhao D, Aljumaily R., J Clin Oncol 36, 2018 (suppl 5S; abstr 208), 1/2018
• Effect of Body Mass Index and Albumin level on Outcomes of Patients Receiving Anti PD-1/PD-L1 Therapy
  Ibrahimi S, Mukherjee S, Roman D, King C, Machiorlatti M, Aljumaily R., J Clin Oncol 36, 2018 (suppl 5S; abstr 213), 1/2018
• Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia
  Mukherjee S, Machiorlatti M, Khalid B, Vidal G. S, Holter Charkrabarty J, & Cherry M. A, Blood, 130 (Suppl 1), 3594, 12/2017
• Join now to see all

Lectures

• Phase II study of trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma... 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
• On the Shoulders of Giants: Historical Approaches to Immunotherapy in Solid Tumors 
  ASCO annual meeting, Chicago, IL - 6/2017
• NANETS Regional NET Education: Multidisciplinary Management of NET Cancers 
  North American Neuroendocrine Tumor Society Regional meeting, Oklahoma City, OK - 11/2017